California, USA (CU)_ The initial findings from the much awaited trial evaluating the efficacy and safety of Pfizer and BioNTech’s COVID-19 vaccination for children under the age 12 demonstrated encouraging results. The initial results from the pharmaceutical firms’ study show that the vaccination is safe for youngsters and induces an active antibody response against the virus. The decision to vaccinate children comes due to rising pediatric cases of COVID-19 in the midst of a countrywide outbreak.
According to Pfizer and BioNTech, a two-dose regimen of 10μg (micrograms) delivered with a…
